Replies to post #232734 on NorthWest Biotherapeutics Inc (NWBO)

[marzan]

Thanks senti. Interesting to see the chronology of events in the past. Like HDG in the AMRN board, you are our record keeper. We got a great team and we are going to be doing real well soon, imo.

[biosectinvestor]

I will have to answer you later Senti. But while I appreciate your answers, they are not correct on multiple levels, including on the placebo patients and a partial halt in enrollment to ensure that no more placebo patients are experimented on when it is already apparent that they are being denied a treatment that extends survival substantially.

You’re also incorrect on the safety/efficacy, and if I have to provide the link later, I will.

[biosectinvestor]

No I meant hyper progression, pseudoprogression has been anticipated for some time... therefore it was not a true safety issue. There were questions of about trial data being potentially inacurrate in this context, but there is no sign that that would have suggested either a safety issue (which would be hyperprogression) or that they were confused enough, given survival stats, that it would have been declared futile. The futility fears are born of paranoia about regulatory agencies that I find quaint, but unrealistic from experience. This was not a replay of Dendreon, which actually did have problems with its trial, despite the groans of long’s there, and ultimately was approved. Their problem ultimately was production and that the product itself was not ready for commercialization once it was approved.

[biosectinvestor]

Intent and actuality are two different things. All anyone has for intent is an old slide... I’ll take a court ruling, based upon a vigorous representation of both sides of an argument with competent representation on both sides and a directly on point answer from a Federal judge, without qualification any day over this nonsense.